Back

Akeso starts global Phase III trial of cadonilimab in advanced gastric cancer

Verifying
  • Akeso enrolled the first patient in the global COMPASSION-37 Phase III gastric cancer trial.
  • COMPASSION-37 will compare cadonilimab plus chemotherapy with chemotherapy-based regimens including nivolumab.
  • COMPASSION-15 enrolled 610 patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.